---
title: "Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise"
description: "Zai Lab's new drug application for KarXT, aimed at treating schizophrenia in adults, has been accepted by China's National Medical Products Administration. The application is supported by results from"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/225375643.md"
published_at: "2025-01-17T15:20:49.000Z"
---

# Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise

> Zai Lab's new drug application for KarXT, aimed at treating schizophrenia in adults, has been accepted by China's National Medical Products Administration. The application is supported by results from various studies, including a phase 1 pharmacokinetics study and a phase 3 study in China. Following the announcement, Zai Lab's shares rose by 2.1%.

Zai Lab said Friday that its new drug application for KarXT to treat adult patients with schizophrenia was accepted by China's National Medical Products Administration.

The application is backed by results from a phase 1 China pharmacokinetics study, the phase 3 China study and data from global Emergent clinical programs, according to the company.

KarXT, or xanomeline and trospium chloride, showed a reduction in positive and negative syndrome scale total score from baseline in the China phase 3 study, Zai Lab added.

Shares of Zai Lab were up 2.1% in recent trading.

### Related Stocks

- [ZLAB.US - Zai Lab](https://longbridge.com/en/quote/ZLAB.US.md)
- [09688.HK - ZAI LAB](https://longbridge.com/en/quote/09688.HK.md)
- [ING.US - ING Groep](https://longbridge.com/en/quote/ING.US.md)
- [DRUG.AU - BetaShares Holdings Pty Ltd.](https://longbridge.com/en/quote/DRUG.AU.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Guardant Health｜10-K：2025 财年营收 9.82 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276387081.md) |
| 华尔街重回 “镀金时代”：六大行掌门人年薪均超 4000 万，刷新 08 年危机后上限 | 华尔街六大银行首席执行官的年薪均超过 4000 万美元，刷新了 2008 年金融危机后的纪录。美国银行 CEO Brian Moynihan 薪酬 4100 万美元，花旗银行 CEO Jane Fraser 薪酬 4200 万美元。行业盈利 | [Link](https://longbridge.com/en/news/276004958.md) |
| Newamsterdam Pharma｜8-K：2025 财年营收 22.5 百万美元 |  | [Link](https://longbridge.com/en/news/276224188.md) |
| Select 医药控股｜10-K：2025 财年营收 54.53 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276384073.md) |
| Select 医药控股｜8-K：2025 财年 Q4 营收 13.97 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276382961.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.